Cisplatin/carboplatin is named as an intervention in 18 current clinical trials in our China, USA and UK registers. 11 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hansoh BioMedical R&D Company (2). The most-studied condition is NSCLC.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| NSCLC | 2 |
| Advanced Solid Tumors | 2 |
| Advanced Solid Tumor | 2 |
| Cervical Cancer | 2 |
| Head and Neck Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Non-small Cell Lung Cancer | 1 |
| Non-Small Cell Lung Cancer NSCLC | 1 |
| Non-Squamous Non Small Cell Lung Cancer | 1 |
| Cancer | 1 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| CRC (Colorectal Cancer) | 1 |
| Non Small Cell Lung Cancer (Squamous or Non Squamous) | 1 |
| Stage 4 NSCLC | 1 |
| Carcinoma, Small Cell Lung | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Pancreatic Ductal Adenocarcinoma (mPDAC) | 1 |
| Limited-stage Small Cell Lung Cancer (LS-SCLC) | 1 |
| Urothelial Carcinoma | 1 |
| Triple Negative Breast Cancer Metastatic | 1 |
| Advanced Non-small Cell Lung Cancer (NSCLC) | 1 |
| EGFR Exon 19 Deletion Mutation | 1 |
| EGFR Exon 21 Mutation | 1 |
| EGFR Exon 21 L858R Mutation | 1 |
| Locally Advanced or Metastatic NSCLC | 1 |
| Esophageal Squamous Cell Carcinoma (ESCC) | 1 |
| Lead sponsor | Trials |
|---|---|
| Hansoh BioMedical R&D Company | 2 |
| ALX Oncology Inc. | 1 |
| Revolution Medicines, Inc. | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Eikon Therapeutics | 1 |
| EpicentRx, Inc. | 1 |
| Haisco Pharmaceutical Group Co., Ltd. | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 1 |
| Lee's Pharmaceutical Limited | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| Shandong New Time Pharmaceutical Co., LTD | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 1 |
+ 2 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 13 | 8 |
| Clinical trials in USA | 5 | 3 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
18 current trials in our China, USA and UK registers name Cisplatin/carboplatin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 18 trials are recruiting: 8 with sites in China and 3 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hansoh BioMedical R&D Company (2), ALX Oncology Inc (1), Revolution Medicines, Inc (1) and Alterome Therapeutics, Inc (1), among 17 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cisplatin/carboplatin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cisplatin/carboplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cisplatin/carboplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.